The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

Publication | Open Access

DOI Full Paper Access

158

Citations

References

2012

Year

Alan K. Burnett, Robert K. Hills, Ann E. Hunter, D Milligan, William J. Kell, Keith Wheatley, J. A. Liu Yin, Mary Frances McMullin, Helen Dignum, David Bowen,

Leukemia

Hematological MalignancyOncologyGemtuzumab OzogamicinMixed-phenotype Acute LeukemiaHematologyImmunologyPharmacotherapyLrf Aml14MedicineOlder PatientsCancer ResearchMyeloid Neoplasia